bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major Read more about bluebird bio Announces Global Regulatory Strategy for LentiGlobin BB305 in Beta-Thalassemia Major
bluebird bio Reports First Quarter 2015 Financial Results and Business Updates Read more about bluebird bio Reports First Quarter 2015 Financial Results and Business Updates
bluebird bio Announces Participation at Two Upcoming Health Care Conferences Read more about bluebird bio Announces Participation at Two Upcoming Health Care Conferences
bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day Read more about bluebird bio to Present at Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day
bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress
bluebird bio Announces Participation in Upcoming Investor Conferences Read more about bluebird bio Announces Participation in Upcoming Investor Conferences
bluebird bio to Present at the Leerink Global Healthcare Conference Read more about bluebird bio to Present at the Leerink Global Healthcare Conference
FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major Read more about FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major
bluebird bio Announces Transition of Chief Scientific Officer Read more about bluebird bio Announces Transition of Chief Scientific Officer
bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 33rd Annual J.P. Morgan Healthcare Conference